Chen Chu-Shih, Matsuoka Rumiko, Arai Shoichi, Momiyama Yukihiko, Murakami Haruka, Kuno Shin-ya, Ishikawa Kaori, Nakada Kazuto, Tawata Masato, Hayashi Jun-Ichi
Institute of Biological Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8572.
J Biochem. 2004 Feb;135(2):237-43. doi: 10.1093/jb/mvh028.
To determine the pathogenicities of mutated mtDNAs in patients with respiration defects, the possible involvement of nuclear DNA mutations has to be excluded, since respiratory function is controlled by both nuclear DNA and mtDNA. This was achieved by showing that the mutated mtDNAs and respiration defects were co-transferred from patients to mtDNA-less human cells, and the resultant cybrid clones carrying mutated mtDNAs expressed respiration defects. To decide whether the cybrid clones expressed respiration defects, in this study the lowest limits of normal respiratory function were evaluated by transfer of mtDNAs from 54 normal subjects to mtDNA-less HeLa cells. The resultant cybrid clones showed that 71% respiratory function was the lowest limit of mtDNAs from normal subjects. On the other hand, cybrid clones carrying pathogenic mtDNAs from patients with mitochondrial diseases showed 0-64% respiratory function, suggesting that less than 71% respiratory function in cybrid clones should be a reliable indicator of whether the mutated mtDNAs of the patients were pathogenic.
为了确定呼吸功能缺陷患者中突变线粒体DNA(mtDNA)的致病性,必须排除核DNA突变的可能影响,因为呼吸功能受核DNA和mtDNA共同控制。这是通过以下方式实现的:将突变的mtDNA和呼吸功能缺陷从患者共同转移到无mtDNA的人类细胞中,携带突变mtDNA的所得胞质杂种克隆表现出呼吸功能缺陷。为了确定胞质杂种克隆是否表现出呼吸功能缺陷,在本研究中,通过将来自54名正常受试者的mtDNA转移到无mtDNA的HeLa细胞中,评估了正常呼吸功能的最低限度。所得的胞质杂种克隆表明,71%的呼吸功能是正常受试者mtDNA的最低限度。另一方面,携带线粒体疾病患者致病性mtDNA的胞质杂种克隆表现出0 - 64%的呼吸功能,这表明胞质杂种克隆中低于71%的呼吸功能应是患者突变mtDNA是否致病的可靠指标。